托吡酯治疗特发性震颤的临床疗效观察

Clinical observation of topiramate in the treatment of essential tremor

目的:探讨托吡酯治疗特发性震颤的疗效及安全性。方法:连续收集2017年10月—2019年12月在本院门诊及住院部经临床诊断为特发性震颤的患者80例,随机分为托吡酯组40例和普萘洛尔组40例,分别给予托吡酯或普萘洛尔治疗,每3 d加量,观察4周,在用药前及用药后4周分别用特发性震颤等级评定量表(the essential tremor rating assessment scale,TETRAS)进行震颤评分,评估患者使用药物治疗的疗效及不良反应。结果:托吡酯组的震颤评分显著低于普萘洛尔组(P<0.05);托吡酯组的总有效率(显效+有效)为92.5%,普萘洛尔组为72.5%,差异有统计学意义(P<0.05);不良反应方面托吡酯组明显少于普萘洛尔组(22.5%vs.45.0%,P<0.05)。结论:托吡酯对于特发性震颤的治疗是安全有效的,不良反应轻微,可以作为特发性震颤的首选用药。

Objective:To investigate the efficacy and safety of topiramate in the treatment of essential tremor.Methods:80 patients were collected who were clinically diagnosed as essential tremor in the outpatient and inpatient department of Lianyungang second people’s Hospital from October 2017 to December 2019.Every subject was randomly treated with topiramate or propranolol for 4 weeks.The essential tremor rating assessment scale(TETRAS)score was used before and 4 weeks after treatment to assess the efficacy and adverse effect of drugs were also evaluated.Results:Finally,80 patients were enrolled in the study.After drug treatment,the tremor score in topiramate group was significantly lower than that in propranolol group(P<0.05).The total effective rate in topiramate group and propranolol group was respectively 92.50%and 72.50%.The difference about curative effect between the two groups was statistically significant(22.5%vs.45.0%,P<0.05).The adverse effect in topiramate group was significantly less than that in propranolol group(P<0.05).Conclusion:Topiramate is an effective and safe drug in the treatment of essential tremor with mild side effects,so it can be used as first choice for essential tremor therapy.